Self Study 2024 Release II Bundle

Type: Bundle•Format: On-demand

The 2024 BCOP Self-Study Bundle Release II offers 10 BCOP CE hours and ACPE CE hours. All self-study modules are on-demand and allow you to review and complete your learning at your convenience, and claim your credits for up to one year following the release of the bundle.

This Self-Study Release II bundle contains the following modules:

  • Module 1: Neoadjuvant Immunotherapy Updates in NSCLC, Colon, and Rectal Cancer (2.00 BCOP/ACPE CE HOURS)
  • Module 2: ESR1 Mutations in Metastatic Breast Cancer (2.00 BCOP/ACPE CE HOURS)
  • Module 3: Adolescent/Young Adult Survivorship (Healthcare Disparities as well as Long-Term Mortality) (1.50 BCOP/ACPE CE HOURS)
  • Module 4: Treatment Updates in Myelodysplastic Syndrome (2.50 BCOP/ACPE CE HOURS)
  • Module 5 : Bispecific T-Cell Engager Therapy: Hematologic Malignancies and Solid Tumors (2.0 BCOP/ACPE CE HOURS)

Get the bundle

Course Learning Objectives

UAN# 0465-0000-24-105-H01-P

Author: Sarah Shockley, PharmD, BCOP

Learning Objectives

  1. Apply recent advances in the use of pembrolizumab in the neoadjuvant setting to early-stage NSCLC patients.
  2. Review the safety and efficacy data of dostarlimab in the neoadjuvant setting in locally advanced rectal cancer.
  3. Interpret current evidence with predictive biomarkers for regimen selection in the neoadjuvant setting for rectal and colon cancer.

UAN# 0465-0000-24-106-H01-P

Author: Amber B. Cipriani, PharmD, BCOP

Learning Objectives

  1. Describe the prevalence and biologic impact of ESR1 mutations observed metastatic breast cancer.
  2. Review approaches for molecular monitoring and therapy adjustment in patients with HR+ HER2- metastatic breast cancer on endocrine therapy.
  3. Compare and contrast available selective estrogen receptor degraders (SERDs) when used in mBC patients with ESR1 alterations.

UAN# 0465-0000-24-107-H01-P

Author: Taylor Dennison, PharmD, BCOP

Learning Objectives

  1. Review the multifaceted burdens survivors of adolescent and young adult cancer must face as they navigate their long-term care
  2. Analyze the development of comorbidities in survivors of adolescent and young adult cancer
  3. Understand long-term mortality and survival discrepancies within survivors of adolescent and young adult cancer

UAN# 0465-0000-24-108-H01-P

Author: Rebecca Hunt, PharmD, BCOP

Learning Objectives

  1. Recognize the place in therapy of novel treatment strategies for the management of MDS
  2. Recall common and serious adverse events associated with novel therapies for the treatment of MDS
  3. Evaluate the clinical outcomes for novel treatment strategies for the management of MDS
  4. Devise a treatment plan for a patient with newly diagnosed or relapsed/refractory MDS

UAN# 0465-0000-24-109-H01-P

Author: Grace Baek, PharmD, BCOP

Learning Objectives

  1. Summarize bispecific T-cell engagers’ place in therapy for solid and hematologic malignancies.
  2. Describe toxicities of bispecific T-cell engagers (Bites).
  3. Construct a supportive care plan that incorporates evidence-based strategies for preventing and managing therapy-related toxicities of bispecific T-cell engagers (Bites).
  4. Analyze controversies and future directions associated with bispecific T-cell engager (Bite) therapy.

Knowledge Courses for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.